George Elston - Feb 9, 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2025
Transactions value $
$0
Form type
4
Date filed
2/11/2025, 06:19 PM
Previous filing
Jan 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +5.83K +8.37% $0.00 75.6K Feb 9, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5.83K -100% $0.00 0 Feb 9, 2025 Common Stock 5.83K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,150 shares acquired on January 31, 2025 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.